Study: EDP-305 for the Treatment of Primary Biliary Cholangitis
source: pixabay.com

Study: EDP-305 for the Treatment of Primary Biliary Cholangitis

Enanta Pharmaceuticals has recently released the results from the second phase of its INTREPID trial, which studied EDP-305 as a treatment for primary biliary cholangitis (PBC). The results were positive,…

Continue Reading Study: EDP-305 for the Treatment of Primary Biliary Cholangitis
Join This Webcast to Hear the Latest Update for a Phase IIb Nonalcoholic Steatohepatitis Trial
source: pixabay.com

Join This Webcast to Hear the Latest Update for a Phase IIb Nonalcoholic Steatohepatitis Trial

According to a story from Biotech-365, the biopharmaceutical company Inventiva has been forced to change its plans to announce the latest updates for its phase IIb clinical trial. This clinical…

Continue Reading Join This Webcast to Hear the Latest Update for a Phase IIb Nonalcoholic Steatohepatitis Trial
Study: Viking Therapeutics Evaluates VK2809 for Treatment of Non-Alcoholic Steatohepatitis (NASH)
luvqs / Pixabay

Study: Viking Therapeutics Evaluates VK2809 for Treatment of Non-Alcoholic Steatohepatitis (NASH)

  The FDA has recently approved of Viking Therapeutics' Investigational New Drug (IND) application, which allows patients to enroll in their clinical trials. In order to qualify for these trials,…

Continue Reading Study: Viking Therapeutics Evaluates VK2809 for Treatment of Non-Alcoholic Steatohepatitis (NASH)
Potential Treatment for Nonalcoholic Steatohepatitis Earns Fast Track Designation
sms467 / Pixabay

Potential Treatment for Nonalcoholic Steatohepatitis Earns Fast Track Designation

According to a story from sectorpublishingintelligence.co.uk, the drug company INVENTIVA's lead product candidate, known as lanifibranor, has earned Fast Track Designation from the US Food and Drug Administration (FDA) as…

Continue Reading Potential Treatment for Nonalcoholic Steatohepatitis Earns Fast Track Designation
Positive Results in Mouse Model for Experimental Drug Treating Liver Scarring Associated With Nonalcoholic Steatohepatitis (NASH)
Alexas_Fotos / Pixabay

Positive Results in Mouse Model for Experimental Drug Treating Liver Scarring Associated With Nonalcoholic Steatohepatitis (NASH)

According to a story from globenewswire.com, the biopharmaceutical company ContraVir Pharmaceuticals, Inc. has recently announced that its experimental drug CRV431 was able to successfully decrease scarring of the liver in…

Continue Reading Positive Results in Mouse Model for Experimental Drug Treating Liver Scarring Associated With Nonalcoholic Steatohepatitis (NASH)

The FDA’s Director of the Center for Drug Evaluation Discusses Accelerated Approvals

  In the mid-1980s the FDA was criticized for being slow in approving new drugs. In fact, a commission was formed as a result of the mounting criticism. Janet Woodcock,…

Continue Reading The FDA’s Director of the Center for Drug Evaluation Discusses Accelerated Approvals

Drug Start Up Founder Says Drugs Will Work For You– But They Don’t Know Why

Although somewhat of an exaggeration, the title of this article falls in line with the thinking of Insitro’s founder, Daphne Koller. In a recent interview with Bloomberg, Koller said that…

Continue Reading Drug Start Up Founder Says Drugs Will Work For You– But They Don’t Know Why

New Potential Primary Biliary Cholangitis Treatment Granted Breakthrough Therapy Designation

Researchers at GENFIT are excited about promising results from studies investigating a new potential therapy for PBC and NASH, two rare liver diseases. Primary Biliary Cholangitis Primary biliary cholangitis (PBC)…

Continue Reading New Potential Primary Biliary Cholangitis Treatment Granted Breakthrough Therapy Designation
Phase 3 Study Data Shows Obeticholic Acid Could Treat NASH-Linked Fibrosis
Source: Pixabay.com

Phase 3 Study Data Shows Obeticholic Acid Could Treat NASH-Linked Fibrosis

According to a press release from American biotechnology company Intercept Pharmaceuticals, the company recently released additional data supporting its phase 3 clinical trial of obeticholic acid (OCA) in the treatment…

Continue Reading Phase 3 Study Data Shows Obeticholic Acid Could Treat NASH-Linked Fibrosis

A Noninvasive Stool Test Could Identify Cirrhosis In Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

Nonalcoholic fatty liver disease (NAFLD) is a condition in which the buildup of fat in the liver poses health concerns. Nonalcoholic Steatohepatitis (NASH) is a more severe, and more rare…

Continue Reading A Noninvasive Stool Test Could Identify Cirrhosis In Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

Biotech Companies are Increasingly Focused on Deadly Diseases With Significant Unmet Need

According to a story from finanznachrichten.de, biotechnology companies are starting to set their sights on treating deadly diseases that are lacking effective treatment options, including some diseases that are considered…

Continue Reading Biotech Companies are Increasingly Focused on Deadly Diseases With Significant Unmet Need

Transplant Surgeon’s Perspective on How We Evaluate Who Receives a Liver

How Liver Transplant Recipients are Selected Liver transplant recipients in the United States are selected according to their MELD score. This number is calculated from lab values. It aims to…

Continue Reading Transplant Surgeon’s Perspective on How We Evaluate Who Receives a Liver
Clinical Trials for Nonalcoholic Steatohepatitis Drugs Are Beginning to Proliferate, But Are They Any Good?
stevepb / Pixabay

Clinical Trials for Nonalcoholic Steatohepatitis Drugs Are Beginning to Proliferate, But Are They Any Good?

According to a story from Andre Eger, the drug developer Gilead recently had the misfortune to announce that its clinical trial testing an experimental drug for late stage nonalcoholic steatohepatitis…

Continue Reading Clinical Trials for Nonalcoholic Steatohepatitis Drugs Are Beginning to Proliferate, But Are They Any Good?

First Patient Dosed in Phase 1b Trial Aiming to Inhibit the Progression of Nonalcoholic Steatohepatitis

Nonalcoholic fatty liver disease (NAFLD) is a condition which causes fat to accumulate in the liver. Nonalcoholic steatohepatitis (NASH) is a severe form of the disease in which the patient also…

Continue Reading First Patient Dosed in Phase 1b Trial Aiming to Inhibit the Progression of Nonalcoholic Steatohepatitis

Making Strides Towards New Treatment Options for Nonalcoholic Steatohepatitis

Nonalcoholic steatohepatitis (NASH), is condition most commonly caused by obesity or type 2 diabetes. It can result in fibrosis, complications in the lung and cardiac system, liver cancer, liver cirrhosis,…

Continue Reading Making Strides Towards New Treatment Options for Nonalcoholic Steatohepatitis
Drug Fails to Make a Difference in Nonalcoholic Steatohepatitis
JeongGuHyeok / Pixabay

Drug Fails to Make a Difference in Nonalcoholic Steatohepatitis

According to a story from Proactive Investors, the biotechnology company Conatus Pharmaceuticals recently reported that the company's drug Emricasan failed to achieve the primary endpoint in a Phase 2b clinical…

Continue Reading Drug Fails to Make a Difference in Nonalcoholic Steatohepatitis

Nonalcoholic Steatohepatitis Study Indicates Continual Treatment Increases Survival

Nonalcoholic fatty liver disease (NAFLD) is exactly what it sounds like. It's caused by a buildup of fat cells in the liver, resulting in many complications caused by the thickening…

Continue Reading Nonalcoholic Steatohepatitis Study Indicates Continual Treatment Increases Survival
Close Menu